Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun’s Halol Site Out Of Compliance Rut, Could Add Some SPARC Too

Executive Summary

Sun's Halol manufacturing facility is over the compliance hump, receiving an EIR [Establishment Inspection Report] from the US FDA. The site, seen as core to India's top ranked firm's promising filings, including injectables, is also expected to lift the prospects of Sun's spin-off R&D arm, SPARC.


Related Content

Xelpros Approval Adds Spark To Sun’s Site Too?
India Pharma Q1 Preview: Home Gains But Subdued US Growth
Sun’s Key Halol Plant Flunks FDA Inspection Again
Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices
Sun Recruits Ex-Cipla Manufacturing Veteran In Compliance Push
SPARC Pins Hope On Halol Plant For Elepsia FDA Nod But Has Plan B
Little Spark Yet For Xelpros Amid New CRL


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts